Johnston Pain Management PA
Johnston Pain Management PA was paid $2.70M by Medicaid between Mar 2018 and Dec 2024, across 24 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoJOHNSTON PAIN MANAGEMENT PA
JACKSONVILLE, NC 28546
JACKSONVILLE, NC 28546
33aNPI1184705865assigned 10/18/2006
33bProvider typeSpecialist
28Total paid$2.70M
24GClaims55,714
24DCodes billed24
24AFirst – last monthMar 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in North Carolina
Rank by total paid#18 of 172
Median peer was paid$83K
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,320 | $35K | |
| 2019 | 7,015 | $324K | |
| 2020 | 7,317 | $438K | |
| 2021 | 10,365 | $527K | |
| 2022 | 11,200 | $508K | |
| 2023 | 9,525 | $463K | |
| 2024incomplete | 8,972 | $406K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 22,089 | 17,335 | $931K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 22% | 4,884 | 3,862 | $587K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15% | 6,862 | 5,304 | $414K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 14,129 | 11,335 | $401K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 2,070 | 1,600 | $310K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 345 | 298 | $19K |
| 62323 | <1% | 110 | 96 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 128 | 101 | $9K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 128 | 103 | $7K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,314 | 1,014 | $4K |
| 95923 | <1% | 140 | 58 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 13 | 12 | $1K |
12 more codes
| 95921 | <1% | 140 | $1K | |
| 93923 | <1% | 141 | $967.86 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 22 | $801.02 |
| J3490 | Unclassified drugs | <1% | 1,209 | $509.62 |
| A4550 | Surgical trays | <1% | 1,390 | $319.89 |
| 93040 | <1% | 97 | $184.46 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 224 | $11.60 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 151 | $0.00 |
| 96101 | 0% | 13 | $0.00 | |
| A4208 | Syringe with needle, sterile 3 cc, each | 0% | 30 | $0.00 |
| A4215 | Needle, sterile, any size, each | 0% | 13 | $0.00 |
| 94761 | 0% | 72 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSTON, SCOTT (OWNER)